Markets:

Overview

News

Currencies

International

Treasuries

Merck & Co (NY:MRK)

110.63 -0.36 (-0.32%)

Streaming Delayed Price Updated: 11:06 AM EST, Jan 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2

...

23 24 25 26 27 28 29 30 31

...

99 100 Next >

ImmunityBio Surges On FDA Green Light For Expanded Bladder Cancer Vaccine Access — Retail Buzz Intensifies ↗

February 20, 2025

The company said that Merck’s TICE BCG shortages have created a significant hurdle for bladder cancer treatment.

Via Stocktwits

Securities Fraud Investigation Into Merck & Co (MRK) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

February 19, 2025

From The Law Offices of Frank R. Cruz

Via Business Wire

MERCK & CO., INC. (NYSE: MRK) INVESTOR ALERT: Investors With Large Losses in Merck & Co., Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

February 19, 2025

From Bernstein Liebhard LLP

Via GlobeNewswire

Looking Into Merck & Co's Recent Short Interest ↗

February 18, 2025

Via Benzinga

Beyond The Numbers: 13 Analysts Discuss Merck & Co Stock ↗

February 18, 2025

Via Benzinga

Why NYSE:MRK is a Top Pick for Dividend Investors. ↗

February 18, 2025

Why MERCK & CO. INC. (NYSE:MRK) provides a good dividend, while having solid fundamentals.

Via Chartmill

Decoding Merck & Co's Options Activity: What's the Big Picture? ↗

February 13, 2025

Via Benzinga

Trade War Redux: These ETFs Due For Bumpy Ride Thanks To Trump Tariffs On Auto, Pharma, Chip Imports ↗

February 19, 2025

Trump's proposed 25% tariffs on auto, semiconductor, and pharmaceutical imports have rattled markets and could affect ETFs with heavy exposure to these sectors.

Via Benzinga

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Merck & Co.

February 19, 2025

From Faruqi & Faruqi LLP

Via GlobeNewswire

Merck & Co. Stockholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Filed Against MRK

February 18, 2025

From Robbins LLP

Via GlobeNewswire

Recent Filing Shows That Rep. Josh Gottheimer Sold Over $54K Worth of Merck & Co Stock ↗

February 11, 2025

Via Benzinga

Europe Approves Merck's Cancer Drug For Two Indications ↗

February 18, 2025

Merck's Welireg receives conditional EU approval for VHL disease-associated tumors and advanced RCC, expanding its global presence across 30+ countries.

Via Benzinga

This Moderna Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday ↗

February 18, 2025

Via Benzinga

Coinbase To Rally Over 11%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

February 18, 2025

Via Benzinga

WELIREG® (belzutifan) Receives First European Commission Approval for Two Indications

February 18, 2025

From Merck & Co., Inc.

Via Business Wire

Trump's Tax Cut Could Add $4.6 Trillion To Deficit, With $48 Billion Tax Relief For Top 100 Firms: Robert Reich ↗

February 18, 2025

Robert Reich has termed Donald Trump's taxation policies as an "absolutely shameless giveaway," that could shoot up deficit to $4.6 trillion.

Via Benzinga

Topics Government

MRK INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Merck & Co., Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

February 17, 2025

From Bronstein, Gewirtz & Grossman, LLC

Via Business Wire

MRK INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Merck & Co., Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

February 17, 2025

From Robbins Geller Rudman & Dowd LLP

Via Business Wire

MRK Investors Have Opportunity to Lead Merck & Co., Inc. Securities Fraud Lawsuit with the Schall Law Firm

February 15, 2025

From The Schall Law Firm

Via Business Wire

MarketBeat Week in Review – 02/10 - 02/14

February 15, 2025

Despite many negative headlines, stocks are trading near all-time highs; next week will be a shortened trading week, with most of the monthly economic data in

Via MarketBeat

Topics Credit Cards Economy Government

10 Health Care Stocks With Whale Alerts In Today's Session ↗

February 14, 2025

Via Benzinga

In a market where value is scarce, NYSE:MRK offers a refreshing opportunity with its solid fundamentals. ↗

February 14, 2025

MERCK & CO. INC. has caught the attention as a great value stock. NYSE:MRK excels in profitability, solvency, and liquidity, all while being very reasonably priced.

Via Chartmill

MRK INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Merck & Co., Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

February 14, 2025

From Robbins Geller Rudman & Dowd LLP

Via Business Wire

Rosen Law Firm Urges Merck & Co., Inc. (NYSE: MRK) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights

February 13, 2025

From The Rosen Law Firm, P.A.

Via Business Wire

Robert F. Kennedy, Vaccine Skeptic, Confirmed As Trump's Secretary Of Health: Health Care Stocks To Watch ↗

February 13, 2025

The U.S. Senate voted on Thursday to confirm President Donald Trump's nomination of Robert F. Kennedy Jr. to lead the Department of Health and Human Services.

Via Benzinga

Topics Government

3 Blue-Chip Dividend Stocks Trading at Multiyear Lows ↗

February 13, 2025

Via The Motley Fool

Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever. ↗

February 13, 2025

Via The Motley Fool

Rosen Law Firm Encourages Merck & Co. Inc. Investors to Inquire About Securities Class Action Investigation – MRK

February 12, 2025

From The Rosen Law Firm, P.A.

Via Business Wire

Neuphoria Stock Jumps On Triggering $15M Milestone Payment From Merck For Alzheimer's Study: Retail Interest Explodes ↗

February 12, 2025

This payment represents the second milestone in the collaboration between Neuphoria and Merck, with Neuphoria potentially eligible for up to $450 million in additional milestone payments.

Via Stocktwits

Gilead Sciences Beats Q4 EPS Forecast ↗

February 11, 2025

Gilead Sciences reported strong fourth-quarter earnings with significant growth in its HIV and oncology segments.

Via The Motley Fool

< Previous 1 2

...

23 24 25 26 27 28 29 30 31

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.